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Ungurianu1, Oana Cristina Șeremet1, Emil Ștefănescu1 
 
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 
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Abstract Patients with type-2 diabetes mellitus (T2DM) have normal or increased bone mineral 
density (BMD) but despite that, they are characterized by an increased hip and vertebral 
fracture risk that involves the alteration of bone quality and not the reduction in bone 
mass. BMD is utilized for the diagnosis and evaluation of osteoporosis, but BMD itself 
cannot provide an accurate diagnosis of the individuals at increased risk of fracture and, 
therefore, studies have focused on identifying other risk factors that are partially or fully 
independent of BMD.  
The fracture risk score tool-FRAX® models provide information about a 10-year 
probability of osteoporotic fractures, but do not include risk factors specific to illness 
such as diabetes duration, diabetes drug therapy, glycemic control, or the presence of 
micro-vascular complications. Multiple markers have been investigated to provide 
information on the risk of fractures in patients with T2DM such as: advanced glycation 
end products (AGEs), insulin-like growth factor-I (IGF-I), osteocalcin (OC), adiponectin, 
and sclerostin, but epidemiological studies did not provide homogeneous information 
regarding the link between these markers and bone fragility in T2DM subjects. Markers 
that increase the accuracy of fracture risk estimation in patients with T2DM need to be 
identified and employed in current medical practice. 
Keywords  diabetes mellitus, bone fragility, markers of fracture risks 
Highlights  Patients with type 2 diabetes mellitus have significantly higher scores in over-vigilance 
and inhibition schematic domains. 
 Epidemiological studies do not provide unitary information on the association between 
markers of bone fragility and fracture risk in T2DM.   
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Introduction 
According to the American Diabetes Association, 
diabetes is a heterogeneous chronic disease which 
includes the following categories: type-1 diabetes 
(T1DM) generated by beta-cell destruction; T2DM due to 
a progressive loss of beta-cell insulin and insulin 
resistance; and gestational diabetes and other types of 
diabetes caused by other problems. T2DM represents 90-
95% of all types of diabetes (1). The International 
Diabetes Federation (IDF) estimates the global prevalence 
of diabetes in the age group of 20–79 years in 2015 at 415 
million, with an uncertainty range of 340–536 million. 
For the same group, IDF predicted 642 million with an 
unclear range: 521–829 million for 2040 (2). After the 
analysis of the published studies, Kaiser AB and co-
workers estimate that in 2018 there are more than 500 
million cases of T2DM worldwide and this prevalence 
will increase (3). In 2018, in Romania the number of 
patients with diabetes who underwent treatment was 
823,280, out of which 241,600 following insulin therapy 
and 581,680 non-insulin agents (4). 
Individuals with T2DM present normal ranges or 
increased ranges of BMD in comparison with subjects 
without diabetes. Despite that, they are characterized by 
increased fracture risk caused by the alteration of bone 
quality (5). The Rotterdam study evaluated the correlation 
between T2DM and fractures in 6,655 men and women 
aged 55 years or older compared to subjects without 
diabetes. The data from the study show that diabetic 
patients had high BMD and increased fracture risks 
compared to the control group (6). The observational 
study conducted by Leslie WD and co-workers, in which 
6,455 diabetic patients and 55,958 subjects without 
diabetes were included, has revealed diabetes as an 
independent risk factor for major osteoporotic fractures 
(7).  
The association between the duration of the disease, 
glycemic control, the presence of microvascular 
complications, and the risk of fracture have been 
investigated in several other studies. The Manitoba cohort 
which included 57,938 women, 8,840 with diabetes and 
49,098 without diabetes, aged 40 years or more, had 
highlighted that diabetes is a risk factor for major 
osteoporotic fractures only in women who have had the 
illness for a long period of time (more than 10 years) (8). 
Another study conducted by Leslie WD and collaborators 
in which 82,094 diabetic patients and 236,682 non-
diabetic subjects were enrolled highlighted that long-term 
diabetes is correlated with an increased risk of fractures. 
Newly diagnosed patients have a low risk of fractures (9). 
The Blue Mountains Eye Study showed that the duration 
of diabetes for 10 years or more is associated with 
proximal humeral fracture (10). Concerning the glycemic 
ranges and fracture risk, in a meta-analysis published in 
2007 in Osteoporosis International, Vestergaard P found 
no correlation between glycated hemoglobin (HbA1) and 
BMD (11). In contrast, other studies support the 
association between increased fracture risk and poor 
glucose control (12, 13). Patients with T2DM and 
microvascular disease have a compromised cortical bone 
microarchitecture via an increase in cortical porosity (14). 
BMD is utilized in the diagnosis and evaluation of 
osteoporosis, and the most used and validated technique 
for determining BMD is dual energy X-ray 
absorptiometry (DEXA). The international reference for 
the diagnosis of osteoporosis is a T-score equal to or 
lower than -2.5 standard deviation (SD) at the lumbar 
spine or femoral neck and osteopenia as a T-score 
between -1.0 SD and -2.5 SD (15, 16). BMD itself cannot 
provide a good estimation of the individuals at higher risk 
of fracture. Therefore studies have focused on identifying 
other risk factors that are partially or fully independent of 
BMD. The FRAX® models provide information about a 
10-year probability of osteoporotic fractures, with and 
without BMD at the femoral neck (16).  
There is a variant in the Romanian language 
version, which includes 12 items: age/sex/height(cm) 
/weight(kg), fracture history, parental hip fracture, 
active smoking, glucocorticoid therapy, rheumatoid 
arthritis, secondary osteoporosis, minimal alcohol 3 
U/day, and BMD at the femoral neck. The item on 
secondary osteoporosis only mentions insulin-
dependent type-1 diabetes mellitus (T1DM) and not 
T2DM. T2DM represents a risk factor that is 
independent of conventional risk factors. For this 
reason Ferrari SL and collaborators proposed the 
following risk factors specific to the illness: diabetic 
age.> 5 years, diabetic drug therapy (insulin, 
thiazolidinedione, sodium-glucose co-transporter 2-
SGLT2 inhibitors), HbA1c.>7%, micro-vascular 
complications (17). The results of two studies 
published in 2012 in the Journal of Bone and Mineral 
Research suggest the inclusion of diabetes in future 
iterations of FRAX® (18, 19).  
Serum potential markers for bone fragility in 
patients with T2DM 
 Multiple serum markers have been investigated to 
provide information on the risk of fractures in patients 
with T2DM. Serum indicators of bone turnover include 
bone formation markers produced by direct or indirect 
Markers of Bone Fragility in Type-2 Diabetes 
 80 
osteoblasts activity, resorption markers which are derived 
from the skeletal collagen and other indicators.  
 Bone formation indicator consists of osteocalcin, 
alkaline phosphatase, bone-specific alkaline phosphatase, 
procollagen type 1 amino terminal pro-peptide (P1NP), 
procollagen type 1 carboxy-terminal pro-peptide (P1CP), 
and osteoprotegerin (20).  
 Osteocalcin is a protein secreted by osteoblasts. It is 
considered a marker of bone formation, but osteocalcin 
also has metabolic effects. Studies on animal models have 
shown that osteocalcin has a positive impact on insulin 
expression in beta-cells and adiponectin in adipocytes (21, 
22). Clinical trials confirmed the correlation between 
osteocalcin, glucose and adiponectin levels - osteocalcin 
was negatively correlated with plasma glucose levels and 
positively correlated with serum adiponectin and insulin 
sensitivity [23, 24, 25]. Hyperglycemia alters osteocalcin 
secretion and glycemic control improves the osteocalcin 
level [26]. Adiponectin is expressed in bone marrow fat. 
Osteoblastic cells have adiponectin receptors and 
adiponectin participates in the differentiation, 
proliferation and mineralization of osteoblasts (27, 28).  
 Alkaline phosphatase is an enzyme highly expressed 
in bone, liver, and kidney. Increased serum alkaline 
phosphatase levels are found throughout bone growth, in 
the liver and in bone diseases. Alkaline phosphatase is an 
inflammatory mediator and previous works have shown 
an association between alkaline phosphatase levels and 
cardiovascular events (29, 30). The results of studies on 
alkaline phosphatase levels in diabetic patients are 
contradictory. Studies highlighted that diabetic patients 
have a lower, similar or an increased serum alkaline 
phosphatase level compared to the control group. In a 
prospective study, Dutta MK and collaborators have 
evaluated alkaline phosphatase levels in 67 patients with 
T2DM and 137 nondiabetic subjects. The mean alkaline 
phosphatase levels were lower with statistical significance 
in diabetic patients compared to the control group (88.5 ± 
33.3 U/l vs 214.7 ± 59.7 U/l, p ˂ 0.00001) and the authors 
suggested that the low levels of alkaline phosphatase 
reflect a decreased bone turnover and increased osteoclast 
genesis (31). Akin O et al report similar values of alkaline 
phosphatase concentration in a study group and a control 
group, while other researchers have highlighted that the 
mean serum level of alkaline phosphatase in diabetic 
patients with poor glycemic control is significantly higher 
compared to healthy controlled subjects (29, 32). Bone 
alkaline phosphatase is one of the isoforms of the alkaline 
phosphatase on the surface of osteoblasts and it is an 
indicator of osteoblast metabolism (33). Insufficient 
studies are available to establish the correlation between 
bone alkaline phosphatase and the risk of fractures in 
T2DM patients. The “Japanese Population-based 
Osteoporosis Cohort Study” evaluated bone alkaline 
phosphatase in 522 postmenopausal women without 
illness or treatment affecting bone metabolism. The 
results of the study revealed that bone alkaline 
phosphatase was correlated with a risk of vertebral 
fractures in the patients included in the survey (34). In a 
cross-sectional study in which 143 diabetic patients and 
4.054 subjects without diabetes were enrolled no 
differences were found in bone alkaline phosphatase 
between the two groups (33). 
 Type 1 pro-collagen is synthesized and secreted in the 
bone matrix. At this level, pro-collagen peptidases cut 
P1NP from the amino-terminal end and P1CP from the 
carboxy-terminal end, resulting in mature type 1 collagen. 
(35). P1NP and P1CP are standard bone formation 
markers but not currently included in the assessment of 
fracture risks as well as other markers of bone turnover 
due to the lack of conclusive information (36). In a cross-
sectional study in which 155 healthy subjects were 
included, P1NP was inversely correlated with insulin and 
glucose levels (37). In another study in which 183 
postmenopausal females were included, 93 with 
osteoporosis (the study group) and 90 without 
osteoporosis (the control group), the mean P1NP level 
was higher, with statistical significance in the study group 
compared to the control group (38). Liu S et al analyzed 
the level of P1NP in 76 patients with T2DM (19 with 
osteoporosis, 25 with osteopenia, and 32 with preserved 
bone mass). The level of P1NP was significantly higher in 
T2DM patients with preserved bone mass and osteopenia 
than in diabetic patients with osteoporosis (p < 0.05) (39). 
A review published in 2017 in the European Journal of 
Endocrinology, which included the results of 66 studies, 
showed that P1NP levels were lower in patients with 
diabetes compared to control groups (40). The assessment 
of P1CP levels is increased in subjects with T2DM and it 
is an indicator for the diastolic dysfunction and 
progression of diabetic nephropathy (41, 42). 
 Bone resorptive markers are represented by amino-
terminal cross-linked telo-peptide of type-I collagen 
(NTX), carboxy-terminal cross-linked telopeptide of type-
I collagen (CTX), tartrate-resistant acid phosphatase 5b 
(TRAP), receptor activator of nuclear factor kappa beta 
ligand (RANKL), pyridinoline, deoxypyridinoline, 
hydroxyproline (20).  
 The evaluation of bone resorptive markers provides 
inconsistent results about the association of these markers 
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with diabetes. The “Fremantle Diabetes Study” revealed 
higher CTX levels in T1DM male patients (43). A cross-
sectional study evaluated bone resorption markers (CTX 
and TRAP) in 78 T2DM patients compared to 55 subjects 
without diabetes. T2DM patients have decreased levels of 
bone resorptive markers compared to control patients 
(44). Osteoblast cells express RANKL which bind to their 
RANK receptor on the surface of osteoclasts and 
stimulate the differentiation of precursors in mature 
osteoclasts. Osteoprotegerin is secreted by osteoblasts and 
protects the skeletal system from exacerbated bone 
resorption by interacting with RANKL and preventing it 
from binding to RANK (45). Alteration of the 
RANKL/osteoprotegerin pathways have been involved in 
metabolic bone disease, vascular calcification and 
atherogenesis (46). Epidemiological studies do not 
provide homogeneous information on RANKL and 
osteoprotegerin levels in diabetic patients. A case-control 
study evaluated RANKL, osteoprotegerin levels in 42 
women (21 women with T2DM and 21 women without 
diabetes). The authors found decreased levels of RANKL 
in the study group compared to the control cohort; the 
osteoprotegerin levels were not significantly different 
between the groups (47). Lappin DF et al evaluated 
plasma levels of bone markers in 63 patients with T1DM 
and 38 control subjects. T1DM patients had significantly 
decreased RANKL levels and increased osteoprotegerin 
compared to the control group (48). In contrast, increased 
levels of RANKL and increased osteoprotegerin were 
found in 40 young patients with T1DM compared to 40 
healthy control subjects (49). 
 Other studied serum markers of bone fragility in 
diabetes are AGEs, IGF-I, and sclerostin. 
 AGEs are formed by the non-enzymatic glycoxidation 
of the protein-amino group. AGEs accumulate in tissues 
and are involved in the occurrence of the chronic 
complications of diabetes. The receptors for AGEs are 
expressed in the human bone and their activation 
generates synthesis inhibition of type 1 collagen and 
osteocalcin (50, 51). Thus, AGEs generate osteoblastic 
dysfunction and increased osteoclast activity (52, 53). 
One of the AGEs is characterized by pentosidine. 
Pentosidine content in cortical or trabecular bone was 
associated with the deterioration of bone quality (54, 55). 
Yamamoto T and coworkers have investigated the 
correlation between serum pentosidine concentration and 
vertebral fractures in 77 men and 76 postmenopausal 
women with T2DM. The authors conclude that 
pentosidine concentration is correlated with vertebral 
fractures in postmenopausal diabetic women, independent 
of BMD (56). In a multi-center study in which 271 
nondiabetic patients with osteoporosis were included, 
urinary pentosidine levels at baseline were increased and 
predicted vertebral fractures under bisphosphonate 
therapy (57). A cohort study conducted by Schwartz AV 
highlighted that urine pentosidine concentrations were 
higher in older individuals with T2DM and predict future 
facture (58).  
 Bone mass is regulated by hormones and local factors; 
IGF-I is synthesized in the liver and osteoblasts and exerts 
the anabolic effects of bone. Experimental studies 
highlighted that IGF-I stimulates the synthesis of 
deoxyribonucleic acid, collagen, and non-collagenous 
protein; reduce collagen degradation in bone cell cultures; 
and is essential in bone matrix mineralization (59, 60). 
Increased levels of glucose and AGEs decrease the 
proliferative response of osteoblastic cell to IGF-I and 
secretion of IGF-I by osteoblasts (61, 62). Clinical studies 
show that free and total IGF-I are lower in patients with 
osteoporosis compared to controls (63, 64). Few clinical 
trials have investigated the relationship between IGF-I 
levels and bone metabolism in patients with T2DM. 
Miyake H and collaborators followed the association 
between IGF-I levels and the occurrence of non-vertebral 
osteoporotic fractures in 356 patients with T2DM (168 
postmenopausal women and 188 men). Their results 
showed that decreased IGF-I concentration is correlated 
with an increased occurrence of non-vertebral 
osteoporotic fractures in postmenopausal women with 
T2DM (65). In 2007 and 2011, Kanazawa I et al 
published two studies about the association between IGF-
I concentration and occurrence/severity of vertebral 
fractures in postmenopausal women with T2DM in 
Osteoporosis International. In the first study, they 
included 131 postmenopausal women with T2DM and the 
results showed that IGF-I levels were significantly 
decreased in women with vertebral fractures compared to 
women without fractures (66). In the second study, 813 
patients with T2DM (334 postmenopausal women and 
479 men) were recruited. In postmenopausal women, 
decreased IGF-I levels have been confirmed to be 
correlated with the number of vertebral fractures; in men, 
no association between IGF-I level and vertebral fractures 
was observed (67). The mechanism that associated 
changes of IGF levels in osteoporosis remains unclear, 
but IGF-I levels may predict fractures. 
 Sclerostin is a tiny protein produced by osteocytes and 
it has an anti-anabolic effect on bone formation (68). A 
study that included 74 patients with T2DM highlighted 
that circulating concentrations of sclerostin are higher in 
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individuals with T2DM than in the control group (50 
subjects) and sclerostin levels were positively correlated 
with the duration of diabetes and HbA1c (69). Similar 
results, respectively significantly increased sclerostin 
levels in patients with T2DM versus control groups, have 
been reported by Khalek MAA and collaborators (70).  
Conclusion 
 Subjects with T2DM have normal or increased BMD 
compared to subjects without diabetes, yet despite this, 
they are characterized by increased fracture risk that 
involves the alteration of bone quality. BMD is used in 
the diagnosis and evaluation of osteoporosis, but BMD 
itself cannot provide an optimal diagnosis in the detection 
of patients with high-risk fractures; therefore, surveys 
have focused on identifying other risk factors that are 
partially or fully independent of BMD. The FRAX® 
models provide information about a 10-year probability of 
osteoporotic fractures, but do not include risk factors 
specific to the illness such as: diabetes duration, diabetes 
drug therapy, glycemic control or the presence of 
microvascular complications. Epidemiological studies do 
not provide unitary information on the association 
between markers of bone fragility and fracture risk in 
T2DM. Markers that increase the accuracy of fracture risk 
estimated in patients with T2DM must be identified and 
used in current medical practice. 
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